

Friday, 26 November 2021

- 08:45 – 09:00 Welcome and introduction**
Medical oncologist - Aristotelis Bamias, Athens (GR)
Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
Urologist - Arnulf Stenzl, Tübingen (DE)
- 09:00 - 10:30 Prostate cancer staging in 2021: Where are we, where are we going? (plenary 1)**
Chairs: Radiologist – Raymond Oyen, Leuven (BE)
Radiation oncologist - Michael Pinkawa, Bonn (DE)
Urologist – Philip Cornford, Liverpool (GB)
- 09:00 - 09:10 State of the Art lecture: Strengths and limitations of PSMA PET for primary staging**
Nuclear medicine physician - Stefano Fanti, Bologna (IT)
- 09:10 - 09:30 Should PSMA PET impact on treatment in newly diagnosed PCa (debate yes vs no)?**
Yes: Urologist - Tobias Maurer, Hamburg (DE)
No: Urologist - Jochen Walz, Marseille (FR)
- 09:30 - 09:40 Optimal staging approach in men recurring after primary treatment**
Urologist - Declan Murphy, Melbourne (AU) pre-recording
- 09:40 - 09:50 How to use imaging for treatment monitoring in metastatic prostate cancer**
Radiologist – Tavernaraki Ekaterini, Athens (GR)
- 09:50 - 10:00 Summary and evidence based recommendations**
Urologist - Philip Cornford, Liverpool (GB)
- 10:00 - 10:30 Discussion**
- 10.30 - 11.00 Coffee break and e-poster viewing**
- 11:00 - 12:45 Prostate cancer : multi-disciplinary case discussions from local to systemic disease (plenary 2)**
Chairs: Radiation oncologist - Pierre Blanchard, Villejuif (FR)
Medical oncologist - Silke Gillissen, Bellinzona (CH)
Urologist - Steven Joniau, Leuven (BE)
- 11:00 - 11:35 Multidisciplinary case discussion: Active surveillance**
Moderator and Case presenter: Urologist - Tobias Maurer, Hamburg (DE)
Case discussants: Pathologist - Eva Compérat, Paris (FR)
Urologist - Veeru Kasivisvanathan, London (GB)
Urologist - Juan Gomez Rivas, Madrid (ES)
- 11:35 - 12:10 Multidisciplinary case discussion: Oligo recurrent disease**
Moderator and Case presenter: Urologist - Alberto Briganti, Milan (IT)
Case discussants: Internal medicine – Stefano Fanti, Bologna (IT)
Radiation oncologist - Pierre Blanchard, Villejuif (FR)
Urologist - Steven Joniau, Leuven (BE)
- 12:10 - 12:45 Multidisciplinary case discussion: Newly diagnosed Hormone sensitive metastatic PCa**
Moderator and Case presenter: Medical oncologist - Oraianthi Fiste, Athens (GR)
Case discussants: Urologist - Axel Merseburger, Lübeck (DE)
Radiation oncologist - Stephanie Kroeze, Zurich (CH)
Medical oncologist - Silke Gillissen, Bellinzona (CH)
- 12:45 - 14:00 Lunch break and e-poster viewing**
- 13:00 - 14:00 Lunch Industry session**

- 14:00 - 15:20 Bladder cancer: Bladder preserving strategies in NMIBC (plenary 3)**
 Chairs: Urologist - Morgan Rouprêt, Paris (FR)
 Urologist - Urologist - Axel Merseburger, Lübeck (DE)
 Medical oncologist - Ronald de Wit, Rotterdam (NL)
- 14:00 - 14:10 Use of bio markers in bladder preserving strategies**
 Urologist - Paolo Gontero, Turin (IT)
- 14:10 - 14:20 Innovative approaches for patients who fail after BCG**
 Urologist - Gianluca Giannarini, Udine (IT)
- 14:20 - 14:30 BCG or more?**
 Urologist - Marco Moschini, Lucerne (CH)
- 14:30 - 14:40 How to improve topical therapy**
 Urologist - Fred Witjes, Nijmegen (NL)
- 14:40 - 14:50 Quality of TURBT**
 Urologist - Athanasios Papatsoris, Athens (GR)
- 14:50 - 15:10 Discussion**
- 15:10 – 15:40 Coffee break and e-poster viewing**
- 15:40 - 16:00 EAU Research Foundation session**
 Chairs Urologist – Anders Bjartell, Malmö (SW)
 Epidemiologist - Wim Witjes, Arnhem (NL)
- 15:40 – 15:50 Update on the Prostate Imaging using MRI +/- contrast Enhancement (PRIME) study**
 Urologist - Veeru Kasivisvanathan, London (GB)
- 15:50 – 16:00 Establishment of Patient-Derived Tumor Xenografts to test personalized treatment strategies**
 Urologist - Maarten Albersen, Leuven (BE)
- 16:00 - 17:30 Kidney cancer: Multidisciplinary case discussions (plenary 4)**
 Panel: Radiologist – Raymond Oyen, Leuven (BE)
 Pathologist - Antonio Lopez-Beltran, Lisbon (PT)
 Urological researcher - Kerstin Junker, Homburg (DE)
 Urologist - Axel Bex, London (GB)
 Radiation oncologist - Valérie Fonteyne, Ghent (BE)
 Urologist - Alessandro Volpe, Novara (IT)
 Medical oncologist - Laurence Albiges, Villejuif (FR)
- 16:00 - 16:30 Multidisciplinary case discussion: Oligometastatic disease**
 Case presenter: Urologist - Riccardo Bertolo, Torino (IT)
 Moderator: Medical oncologist - Laurence Albiges, Villejuif (FR)
 Case discussants: same as panel
- 16:30 - 17:00 Multidisciplinary case discussion: When not to do partial nephrectomy**
 Case presenter: Urologist - Alessandro Larcher, Milan (IT)
 Moderator: Urologist - Axel Bex, London (GB)
 Case discussants: same as panel
- 17:00 - 17:30 Multidisciplinary case discussion: Alternative treatment modalities for small renal masses**
 Case presenter: Urologist - Carmen Mir, Barcelona (ES)
 Moderator: Urologist - Alessandro Volpe, Novara (IT)
 Case discussants: same as panel

Saturday, 27 November 2021

08:45 - 10:30 **New trials update (plenary 5)**

Chairs: Medical oncologist - Yohann Loriot, Villejuif (FR)
Urologist - Marco Moschini, Lucerne (CH)
Radiation oncologist - Gert De Meerleer, Leuven (BE)

08:45 - 09:00 **NIMBUS trial - follow up**

Speaker: Urologist - Marc-Oliver Grimm, Jena (DE)
Discussant: Urologist - Axel Merseburger, Lübeck (DE)

09:00 - 09:15 **Flame trial**

Speaker: Radiation oncologist - Linda Kerkmeijer, Nijmegen (NL)
Discussant: Radiotherapist - Bradley Pieters, Amsterdam (NL)

09:15 - 09:30 **IMvigor130**

Speaker: Medical oncologist - Aristotelis Bamias, Athens (GR)
Discussant: Medical oncologist - Thomas Powles, London (GB)

09:30 - 09:45 **Extended vs limited Pelvic Lymph node dissection in prostate cancer**

Speaker: Urologist - Jean Lestingi, Marco Leite (BR)
Discussant: Urologist - Ganesh Palapattu, Ann Arbor (US)

09:45- 10:00 **CLEAR trial**

Speaker: Urologist - Jens Bedke, Tübingen (DE)
Discussant: Medical oncologist - Laurence Albiges, Villejuif (FR)

10:00 - 10:30 **Discussion**

10:30 - 11:00 **Coffee break and e-poster viewing**

11:00 - 11:50 **Multidisciplinary case discussions – Testis (plenary 6)**

Panel: Radiation oncologist - Peter Hoskin, Northwood (GB)
Medical oncologist - Jan Oldenburg, Oslo (NO)
Urologist - Christian Fankhauser, Lucerne (CH)
Pathologist - Maurizio Colecchia, Milan (IT)

11:00 - 11:25 **Multidisciplinary case discussion: Active surveillance**

Case presenter: Medical oncologist - Stefanie Fischer, St. Gallen (CH)
Case discussants: same as panel

11:25 - 11:50 **Multidisciplinary case discussion: Poor prognosis or refractory**

Case presenter: Internal medicine physician - Roubini Zakopoulou, Athens (GR)
Case discussants: Same as panel

11:50 - 12:05 **Announcement 3 best abstract posters**

Chairs: Radiation oncologist - Ananya Choudhury, Manchester (GB)
Urologist - Juan Gomez Rivas, Madrid (ES)
Medical oncologist - Stefanie Fischer, St. Gallen (CH)

12:05 - 12:45 **Oral presentation of the 6 best abstracts**

Chairs: Radiation oncologist - Piet Ost, Ghent (BE)
Urologist - Giorgio Gandaglia, Milan (IT)
Medical oncologist - Silke Gillissen, Bellinzona (CH)

O1 - External validation and addition of PSMA-PET to the most frequently used nomograms for the ff7 prediction of pelvic lymph-node metastases: An international multicenter study
Dennie Meijer, Amsterdam (NL)

O2 - Reproducibility of tumor staging depends on the applied PSMA-radiotracer - A retrospective analysis on the interobserver variability of PSMA-PET/CT
Marinus Jan Hagens, Amsterdam (NL)

O3 - Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1
Arnulf Stenzl, Tübingen (DE)

O4 - Development and validation of a molecular subtype-associated immune prognostic signature for muscle invasive bladder cancer
Zongtai Zheng, Shanghai (CN)

O5 - Updated Overall Survival (OS) with atezolizumab (atezo) monotherapy vs. chemotherapy in untreated locally advanced or metastatic Urothelial Carcinoma (mUC) in the Phase III IMvigor130 study
Aristotelis Bamias, Athens (GR)

O6 - Treatment of EAU intermediate risk category non-muscle invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations. A subgroup analysis of the 'NIMBUS' phase III clinical trial
Marc-Oliver Grimm, Jena (DE)

12:45 - 14:00 Lunch break and e-poster viewing

13:00 - 14:00 Industry session

14:00 - 15:30 Combining immunotherapy with local treatment of GU cancer (plenary 7)

Chairs: Medical oncologist - Maria De Santis, Berlin (DE)
Medical oncologist - Julia Murray, London (GB)
Urologist - Morgan Rouprêt, Paris (FR)

14:00 - 14:15 Understanding checkpoint inhibition to improve patient outcome

Urologist - Jens Bedke, Tübingen (DE)

14:15 - 14:25 Immunotherapy and SBRT

Radiation oncologist - Stephanie Kroeze, Zurich (CH)

14:25 - 14:35 Peri operative immunotherapy in MIBC

Medical oncologist - Andrea Necchi, Milan (IT)

14:35 - 14:45 Radio-immunotherapy for bladder preservation

Radiation oncologist - Ananya Choudhury, Manchester (GB)

14:45 - 14:55 The role of surgery in the era of immunotherapy

Urologist - Arnulf Stenzl, Tübingen (DE)

14:55 - 15:30 Case based discussion

Case presenter and moderator: Medical oncologist - Maria De Santis, Berlin (DE)

15:30 - 16:00 Coffee break and e-poster viewing

16:00 - 17:00 Personalised approaches in GU cancers (plenary 8)

Chairs: Urological researcher - Kerstin Junker, Homburg (DE)
Medical oncologist - Camillo Porta, Pavia (IT)
Pathologist - Antonio Lopez-Beltran, Lisbon (PT)

16:00 - 16:10 Circulating tumour DNA for decision making in high risk and metastatic bladder cancer

Researcher - Lars Dyrskjöt, Aarhus (DK)

16:10 - 16:20 Practical considerations for genetic testing in prostate cancer

Medical oncologist - Elena Castro, Malaga (ES)

16:20 - 16:30 The new WHO classification of kidney tumours

Pathologist - Maria Rosaria Raspollini, Florence (IT)

16:30 - 16:40 PET/CT: which tracer for which patient?

Radiologist - Francesco Ceci, Milan (IT)

16:40 - 17:00 Discussion

Sunday, 28 November 2021

- 08:45 - 10:45 Management of recurrent prostate cancer (plenary 9)**
Chairs: Radiation oncologist - Michael Pinkawa, Bonn (DE)
Medical oncologist - Karim Fizazi, Villejuif (FR)
Urologist - Hein Van Poppel, Leuven (BE)
- 08:45 - 09:10 Salvage radiotherapy: increasing dose and use of ADT?**
Case presentation: Radiation oncologist - Charlien Berghen, Leuven (BE)
Yes: Radiation oncologist - Gert De Meerleer, Leuven (BE) (5 min)
No: Urologist - Athanasios Dellis, Athens (GR)
Rebuttal 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE)
- 09:10 - 09:35 Local management of radio recurrent disease**
Case presentation: Radiation oncologist - Stephanie Kroeze, Zurich (CH) (4 min)
Surgery: Urologist - Axel Heidenreich, Cologne (DE) (5 min)
Focal therapy: Rafael Sanchez Salas, Paris (FR) (5 min)
Rebuttal: 3 min each (6 min)
Conclusion: Urologist - Hein Van Poppel, Leuven (BE) (5 min)
- 09:35 - 10:00 Metastases directed therapy for a recurrent disease, yes or no? debate**
Case presentation: Urologist – Nicola Fossati, Milan (IT) (4 min)
Pro: Radiation oncologist - Thomas Zilli, Geneva (CH) (5 min)
Con: Urologist – Ganesh Palapattu, Ann Arbor (US)
Rebuttal : 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)
- 10:00 - 10:25 Hormone sensitive recurrent disease: How much systemic treatment is necessary?**
Case presentation: Urologist - Christian Fankhauser, Lucerne (CH)
ADT and any combination: Medical oncologist - Chris Sweeney, Boston (US) (5 min)
ADT: Urologist - Bertrand Tombal, Brussels (BE) (5 min)
Rebuttal : 3 min each (6 min)
Conclusion: Medical oncologist - Karim Fizazi, Villejuif (FR) (5 min)
- 10:25 - 10:50 Second line CRPC : Peptide Radioligand Therapy vs second line systemic treatment**
Case presentation: Medical oncologist – Michail Lontos, Athens (GR) (4 min)
Pro: Medical oncologist - Ignacio Duran, Madrid (ES) (5 min)
Con: Urologist - Urologist - Philip Cornford, Liverpool (GB)
Rebuttal : 3 min each (6 min)
Conclusion: Radiation oncologist - Michael Pinkawa, Bonn (DE) (5 min)
- 10:50 - 11:05 Announcement 3 best abstract posters**
Chairs: Urologist - Axel Merseburger, Lübeck (DE)
Medical oncologist - Camillo Porta, Pavia (IT)
Radiation oncologist - Michael Pinkawa, Bonn (DE)
- 11:05 - 11:55 Take home messages**
11:05 - 11:15 Pathologist - Maurizio Coecchia, Milan (IT)
11:15 - 11:25 Radiation oncologist - Michael Pinkawa, Bonn (DE)
11:25 - 11:35 Urologist - Axel Merseburger, Lübeck (DE)
11:35 - 11:45 Radiologist - Raymond Oyen, Leuven (BE)
11:45 - 11:55 Medical oncologist - Camillo Porta, Pavia (IT)
- 11:55 - 12:00 Closing remarks**
Medical oncologist - Aristotelis Bamias, Athens (GR)
Radiation oncologist - Peter Hoskin, Northwood and Manchester (GB)
Urologist - Arnulf Stenzl, Tübingen (DE)